1. Scrip
  2. >>Therapy Areas

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

 
• By Mandy Jackson

Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.

T-cells attacking cancer_1200x675

Juno Therapeutics Inc. has ended development of its CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapy JCAR015 for the treatment of acute lymphoblastic leukemia (ALL) due to safety concerns, answering with certainty the question of whether the company could catch up to its competitors, which will be seek approvals for their CAR-T therapies any day now.

Juno said on March 1 in its fourth quarter and year-end 2016 earnings report that the company and its partner Celgene Corp. ended the pivotal ROCKET clinical trial that...

More from Anticancer

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.